June 5, 2008-The European Medicines Agency (Emea) Has Been Formally Notified By Celgene Europe Limited Of Its Decision To Withdraw The Application For A Centralised Marketing Authorisation For Lenalidomide Celgene Europe (Lenalidomide), 5 Mg And 10 Mg Hard Capsules.
Lenalidomide Celgene Europe was intended to be used for the treatment of anaemia due to myelodysplastic syndromes. It was designated as an orphan medicine for use in this condition.
The whole story can be read here.
No comments:
Post a Comment